Original Article
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
N Engl J Med 2006; 355:1124-1140September 14, 2006
- Abstract
Background
Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis.
Methods
We randomly assigned 281 patients to receive oral fingolimod, at a dose of 1.25 mg or 5.0 mg, or a placebo once daily, and we followed these patients for 6 months with magnetic resonance imaging (MRI) and clinical evaluations (core study, months 0 to 6). The primary end point was the total number of gadolinium-enhanced lesions recorded on T1-weighted MRI at monthly intervals for 6 months. In an extension study in which the investigators and patients remained unaware of the dose assignments (months 7 to 12), patients who received placebo underwent randomization again to one of the fingolimod doses.
Results
A total of 255 patients completed the core study. The median total number of gadolinium-enhanced lesions on MRI was lower with 1.25 mg of fingolimod (1 lesion, P<0.001) and 5.0 mg of fingolimod (3 lesions, P=0.006) than with placebo (5 lesions). The annualized relapse rate was 0.77 in the placebo group, as compared with 0.35 in the group given 1.25 mg of fingolimod (P=0.009) and 0.36 in the group given 5.0 mg of fingolimod (P=0.01). For the 227 patients who completed the extension study, the number of gadolinium-enhanced lesions and relapse rates remained low in the groups that received continuous fingolimod, and both measures decreased in patients who switched from placebo to fingolimod. Adverse events included nasopharyngitis, dyspnea, headache, diarrhea, and nausea. Clinically asymptomatic elevations of alanine aminotransferase levels were more frequent with fingolimod (10 to 12%, vs. 1% in the placebo group). One case of the posterior reversible encephalopathy syndrome occurred in the 5.0-mg group. Fingolimod was also associated with an initial reduction in the heart rate and a modest decrease in the forced expiratory volume in 1 second.
Conclusions
In this proof-of-concept study, fingolimod reduced the number of lesions detected on MRI and clinical disease activity in patients with multiple sclerosis. Evaluation in larger, longer-term studies is warranted. (Clinicaltrials.gov numbers, NCT00333138 [core study] and NCT00235430 [extension].)
Media in This Article
Figure 1
Numbers of Patients Who Underwent Randomization and Who Completed Treatment.Figure 2
Proportions of Patients Who Were Free of Gadolinium-Enhanced Lesions on T1-Weighted MRI at 0 to 6 Months (Panel A) and the Estimated Time to a First Confirmed Relapse (Panel B).Article Activity
- Article
Multiple sclerosis is the most common nontraumatic cause of neurologic disability in young adults.1,2 It is generally believed to be an autoimmune condition in which autoreactive T cells attack myelin sheaths,3 leading to demyelination and axonal damage.4 Currently approved immunomodulating treatments for multiple sclerosis (interferon beta and glatiramer acetate)5-8 reduce relapse rates by about 30%.9 Both these drugs are administered either subcutaneously or intramuscularly, and interferons are associated with systemic reactions in more than 60% of patients,10 with implications for adherence to treatment.11
Fingolimod (FTY720, Novartis Pharma) is an oral sphingosine-1-phosphate receptor modulator. After rapid phosphorylation, fingolimod-P acts as a superagonist of the sphingosine-1-phosphate-1 receptor on thymocytes and lymphocytes and induces aberrant internalization of this receptor, thereby depriving these cells of a signal necessary to egress from secondary lymphoid tissues. The majority of circulating lymphocytes are thus sequestered in lymph nodes, reducing peripheral lymphocyte counts and the recirculation of lymphocytes to the central nervous system.12-15 Lymphocytes in secondary lymphoid organs and those remaining in blood continue to be functional. In laboratory animals, fingolimod does not impair memory T-cell activation or expansion in response to systemic viral infection.16 In animal models of multiple sclerosis, fingolimod prevents the onset of disease and reduces established neurologic deficits.12,17,18
We conducted a double-blind, placebo-controlled, proof-of-concept clinical study to evaluate the efficacy and safety of fingolimod for the treatment of relapsing multiple sclerosis.
Methods
The steering-committee members and the sponsors designed the study. The authors had access to all data, participated in the analysis and interpretation of data, and were members of the publication committee. The academic authors vouch for the completeness and veracity of the data and analyses.
Patients
Eligible patients were 18 to 60 years of age and had a diagnosis of relapsing multiple sclerosis19 and at least one of the following: two or more documented relapses during the previous 2 years, one or more documented relapses in the year before enrollment, and one or more gadolinium-enhanced lesions detected on magnetic resonance imaging (MRI) at screening. Additional eligibility criteria included a score of 0 to 6 on the Expanded Disability Status Scale (EDSS, on which scores range from 0 to 10, with higher scores indicating a greater degree of disability)20 and neurologically stable condition, with no evidence of relapse for at least 30 days before screening and during the screening and baseline phases. Exclusion criteria were use of corticosteroids (within the previous 30 days), immunomodulatory therapy (within the previous 3 months), or immunosuppressive treatment (e.g., azathioprine or methotrexate within 6 months, cyclophosphamide within 12 months, or mitoxantrone or cladribine within 24 months); a history of cardiac conditions that might increase the risk of a decrease in heart rate; a white-cell count of less than 3500 per cubic millimeter; and a lymphocyte count of less than 800 per cubic millimeter.
The study adhered to the International Conference on Harmonization Guidelines for Good Clinical Practice21 and was conducted in accordance with the Declaration of Helsinki.22 An independent external data and safety monitoring board evaluated adverse events and other safety data as well as clinical and MRI efficacy data. All patients gave written informed consent.
Study Design and Randomization
The study included a 6-month double-blind core study (months 0 to 6) and a 6-month extension study during which the investigators and patients were unaware of treatment assignments (months 7 to 12).
In the core study, patients were randomly assigned, in a 1:1:1 ratio, to 1.25 mg of fingolimod, 5.0 mg of fingolimod, or a matching placebo once daily; all drugs were given as capsules. Randomization was stratified according to disease course (relapsing–remitting or secondary progressive) with the use of a centralized automated system that provided randomized packages of the study drug to each center. The medication was prepackaged on the basis of a block size of 3 (1.25 mg, 5.0 mg, and placebo); this information was not disclosed to investigators and monitors.
After the core study, patients could continue in the extension study. Participating patients received a new set of medication and were unaware of the treatment assignment; those who had received active treatment in the core study continued with the same dose, and those who had received placebo were randomly assigned to receive 1.25 or 5.0 mg of fingolimod.
Study visits took place at screening, at baseline, on days 1 and 7, and then monthly for 6 months. In the extension study, visits took place on day 1 and at months 9 and 12. MRI of the brain was performed at baseline, monthly for 6 months, and at month 12, with the use of standard, predefined acquisition settings. T1-weighted, T2-weighted, and proton and density sequences were obtained before the administration of gadolinium. T1-weighted sequences were also obtained after the administration of gadolinium. Vital signs were obtained at each visit, and laboratory and hematologic measures were obtained at baseline, day 1, and months 1, 3, 6, 9, and 12. Electrocardiograms were obtained at baseline, on days 1 and 7, and at months 1, 3, 6, and 12, and 24-hour Holter electrocardiographic monitoring was performed at selected sites at baseline, day 1, and month 3. Pulmonary-function tests, which included the forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and carbon monoxide diffusion capacity, were performed at screening and months 6 and 12. These tests were introduced by means of a protocol amendment and thus were performed in a subgroup of patients. Neurologic evaluations were performed at baseline and every 3 months thereafter with the use of the EDSS and the Multiple Sclerosis Functional Composite (MSFC, data not shown). Relapses were confirmed by the treating physician on the basis of an examination by the EDSS rater who was not otherwise involved in patient care. When warranted, relapses were managed by the treating physician according to a standardized scheme, with up to 1000 mg of methylprednisolone per day given intravenously for 3 to 5 days.
Study End Points and Procedures
As previously suggested for phase 2 proof-of-concept trials in relapsing multiple sclerosis,23,24 the primary efficacy end point of the study was the total number of gadolinium-enhanced lesions per patient recorded on T1-weighted MRI at monthly intervals for 6 months. Secondary MRI variables included the total volume of gadolinium-enhanced lesions per patient, the proportion of patients with gadolinium-enhanced lesions, the total number of new lesions per patient on T2-weighted images, changes in lesion volume on T2-weighted images, and brain volume from baseline to month 6.
Clinical end points included the number of patients remaining free of relapse, the annualized relapse rate, and the time to the first relapse. Confirmed relapse was defined as the occurrence of new symptoms or worsening of previously stable or improving symptoms and signs not associated with fever, lasting more than 24 hours and accompanied by an increase of at least half a point in the EDSS score or 1 point in the score for at least one of the functional systems (excluding the bowel and bladder and mental systems). Neurologic deterioration that was classified by the treating physician as a relapse but that did not fulfill these criteria was documented as an unconfirmed relapse. In the core study, we performed exploratory assessments of disability by comparing scores on the MSFC and EDSS at baseline with scores at month 6. For the extension study, values at baseline and month 6 were compared with values at month 12.
MRI scans were assessed for quality and compliance at the MS-MRI Evaluation Center in Basel without the evaluators' knowledge of treatment assignments or clinical results. Lesion volumes were measured with the use of an interactive digital-analysis program.25 Brain volume was measured with the Structural Image Evaluation Using Normalisation of Atrophy (SIENA) program.26 Neurologic assessments were performed by specially trained,27 independent neurologists who were unaware of the treatment assignments, were not involved in the everyday care of the patients, and had no access to their medical records.
Adverse events were assessed and reported at each visit (scheduled and unscheduled) by the treating physicians. Laboratory evaluations were undertaken at a central laboratory. Laboratory values that might have revealed the treatment assignment (e.g., lymphocyte counts) were not disclosed to treating physicians unless they exceeded prespecified safety limits. In cases of clinical adverse events or notable laboratory abnormalities, the dose of study medication was reduced or withheld at the discretion of the treating neurologist. Rechallenge after improvement was performed at the discretion of the treating neurologist.
Statistical Analysis
Statistical power and sample size were calculated on the basis of data from the Sylvia Lawry Centre for Multiple Sclerosis Research,28 with a nonparametric bootstrap method29 with a two-sided Wilcoxon rank-sum test and a 5% significance level. For a study with 80 patients per group, we estimated that the study would have a power of 78% if the number of post-baseline lesions on MRI was reduced by 50% in the fingolimod groups, as compared with the placebo group. Assuming that we would be able to evaluate data for more than 90% of patients, the enrollment of 72 patients with data that could be evaluated in each group would be sufficient to detect a significant treatment effect of 50% with a power of 75%.
As prespecified, MRI analyses were primarily performed in a population of patients who underwent randomization and who completed 6 months of treatment, had no major protocol violations, and for whom MRI scans were available at baseline and on three or more visits. Use of a per-protocol–like population for MRI analyses is appropriate for a proof-of-concept study. The intention-to-treat population comprised all patients who were randomly assigned to receive at least one dose of study medication and had at least one post-baseline MRI. MRI analyses were repeated for the intention-to-treat population to assess the sensitivity of the results with the population with data that could be evaluated. Clinical outcomes were evaluated in the intention-to-treat population. Safety analyses were undertaken for patients who were randomly assigned to receive at least one dose of study drug and completed at least one safety assessment. Adverse events were analyzed by means of Fisher's exact test.
MRI end points were compared among the groups with the use of nonparametric Wilcoxon rank-sum tests. The probability of a first confirmed relapse was calculated by the Kaplan–Meier method, with between-group comparisons made with the log-rank test. Proportions of patients who were free of relapse at month 6 on the basis of Kaplan–Meier estimates were compared with the use of the z-test. We used a Poisson regression model to compare annualized relapse rates. Baseline characteristics were assessed with Fisher's exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables. P values are based on two-sided tests. No interim analysis was performed. No adjustments were made for multiple comparisons.
When scans were missing, patients discontinued treatment, or MRI was performed within 14 days after corticosteroid treatment and the results were therefore considered invalid, the median of number and volume of gadolinium-enhanced lesions and the number of new lesions on monthly T2-weighted scans available post-baseline was imputed. Each patient therefore had six complete scans, and the totals were compared among treatments with a nonparametric Wilcoxon rank-sum test. Additional analyses were performed with data from the intention-to-treat population and actual lesion counts only (i.e., without imputed data). These analyses included Wilcoxon rank-sum tests for between-group comparisons of the average number of lesions per scan and per patient and generalized estimation equations30 with the use of longitudinal data and adjustment for baseline covariates. The Wilcoxon signed-rank test was used for within-group comparisons of MRI outcomes in the extension study.
Results
Patients
Patients were recruited by investigators from 32 centers in 10 European countries and Canada from May 2003 to April 2004. In the 12-month extension study, the assessment for the last patient was completed in April 2005.
Figure 1Figure 1
Numbers of Patients Who Underwent Randomization and Who Completed Treatment. shows the numbers of patients who were randomly assigned to the three study groups and who completed treatment. Baseline characteristics were similar among the three groups (Table 1Table 1
Baseline Characteristics of the Patients.).MRI Results in the Core Study
The total cumulative numbers of lesions per patient on post-baseline, monthly gadolinium-enhanced, T1-weighted MRI scans were lower in both fingolimod groups than in the placebo group (P<0.001 for the 1.25-mg dose and P=0.006 for the 5.0-mg dose) (Table 2Table 2
MRI and Clinical End Points at 6 Months in the Core Study.).At month 6, the proportion of patients who were free of gadolinium-enhanced lesions was greater in both fingolimod groups than in the placebo group (P<0.001 for both comparisons), with a separation between the curves becoming evident from 2 months onward (Figure 2AFigure 2
Proportions of Patients Who Were Free of Gadolinium-Enhanced Lesions on T1-Weighted MRI at 0 to 6 Months (Panel A) and the Estimated Time to a First Confirmed Relapse (Panel B).). With the exception of the change in brain volume from baseline, all secondary MRI end points differed significantly between the fingolimod groups and the placebo, in each case favoring treatment with fingolimod (Table 2).In the population with data that could be evaluated, only 1% of scans were missing or invalid (i.e., with the use of imputed values), as compared with 6% in the intention-to-treat population. When sensitivity analyses of data with and without imputation were performed for the intention-to-treat population, all MRI findings were similar to those in the population with data that could be evaluated and all significant differences were maintained.
Clinical Outcomes in the Core Study
Although the study was not powered to detect a treatment effect on the relapse end points, significant improvements over placebo were observed in the fingolimod groups, including a relative reduction in the annualized relapse rate (by 53% in the 5.0-mg group and by 55% in the 1.25-mg group) (Table 2). In addition, the estimated time to a first relapse was significantly prolonged in the fingolimod groups (Figure 2B). Inclusion of unconfirmed relapses yielded similar results. There were no significant differences in disability (EDSS scores) at 12 months between the fingolimod groups and the placebo group (Table 2).
Extension Study
Of the 255 patients who completed the core study, 250 (98%) continued in the extension study (Figure 1). A total of 227 of these 250 patients (91%) completed the 6-month extension study, for a total of 12 months in the overall study.
At month 12, the number of gadolinium-enhanced lesions remained low in the two groups of patients who received continuous treatment with fingolimod, whereas the number decreased significantly among the patients who switched from placebo to fingolimod (Table 3Table 3
MRI and Clinical End Points in the Extension Study.). Other MRI variables consistently showed that fingolimod continued to have a marked effect on inflammatory activity, as reflected by MRI findings (Table 3). At month 12, more than 80% of patients who received fingolimod were free of gadolinium-enhanced lesions.Among patients who switched from placebo to fingolimod, the annualized relapse rate was lower during the period of treatment with fingolimod (Table 3). The relapse rates in the groups of patients who received continuous fingolimod remained low during months 7 to 12, with overall 12-month relapse rates of 0.31 and 0.29 for the 1.25-mg dose and the 5.0-mg dose, respectively.
In both groups of patients who received continuous fingolimod, 79% were free of relapse at month 12, whereas 65 to 67% were free of relapse in the groups given placebo and fingolimod. The EDSS scores did not worsen during 12 months of treatment.
Adverse Events
In the core study, the incidence of adverse events was higher in the group of patients who received fingolimod at a dose of 5.0 mg per day than in the group that received the 1.25-mg dose and the placebo group (Table 4Table 4
Adverse Events in the Safety Population of the 6-Month Core Study.). Frequently reported adverse events associated with fingolimod were nasopharyngitis and dyspnea (both mainly in the group of patients who received fingolimod at a dose of 5.0 mg), headache, diarrhea, and nausea. The study medication was discontinued because of adverse events in four patients who received placebo, in five patients who received 1.25 mg of fingolimod, and in eight patients who received 5.0 mg of fingolimod. The incidence of serious adverse events was similar among the study groups (Table 4); no patient died.The overall incidence of adverse events in the extension study was lower than that in the core study, with nasopharyngitis, influenza, and headache reported most frequently (Table 5Table 5
Adverse Events in the Safety Population of the Extension Study.). No infections were reported as serious adverse events in the core study. Two infections were reported as serious adverse events during the extension: one case of facial herpes zoster in a patient who switched from placebo to fingolimod at a dose of 5.0 mg and one case of enterocolitis in a patient who switched from placebo to fingolimod at a dose of 1.25 mg.In the core study, after 10 weeks of treatment with fingolimod at a dose of 5.0 mg, the posterior reversible encephalopathy syndrome developed in a 52-year-old woman. This syndrome was characterized clinically by headache, acute cortical blindness, ophthalmoplegia, dysarthria, and ataxia. MRI showed diffuse areas of hyperintensity in the occipital region and brain stem on T2-weighted scans — findings consistent with the presence of posterior reversible encephalopathy syndrome.31,32 The patient did not have a history of hypertension or renal disease. Neurologic symptoms and the hyperintense areas on MRI began to improve 72 hours after the discontinuation of treatment, leaving a residual right homonymous hemianopia corresponding to a left occipital hyperintensity and mild ataxia, which did not change after 15 months of follow-up.
Clinically asymptomatic lymphopenia and increases in liver enzyme levels (mainly alanine aminotransferase) were the most common laboratory abnormalities. Peripheral-blood lymphocyte counts decreased rapidly to approximately 20 to 30% of the baseline value in both fingolimod groups. During the core study, an increase in the alanine aminotransferase level to three or more times the upper limit of the normal range (≥90 U per liter in women and ≥117 U per liter in men) was more frequent with fingolimod (in 10% of the patients who received 1.25 mg and in 12% of those who received 5 mg) than with placebo (1%; P=0.02 and P<0.005, respectively). Elevations of aspartate aminotransferase levels were uncommon (Table 4), and fingolimod treatment was not associated with elevations of bilirubin or alkaline phosphatase levels (see the Supplementary Appendix, available with the full text of this article at www.nejm.org). Among the 26 patients who received continuous treatment with fingolimod and had alanine aminotransferase levels that were three or more times the upper limit of the normal range, the levels returned to less than three times the upper limit in 13 (to the normal range in 5) without any dose adjustments. Fingolimod was discontinued in the other 13 patients, and alanine aminotransferase levels subsequently returned to less than three times the upper limit of the normal range in all 13. Of four patients in whom fingolimod treatment was resumed, three had alanine aminotransferase levels that remained lower than three times the upper limit of the normal range; treatment with fingolimod was discontinued permanently in one patient. During the core and extension studies, treatment was permanently discontinued in two patients because of elevated liver enzyme levels. No elevations in liver enzyme levels were associated with clinical symptoms.
Within 6 hours after the first dose of fingolimod, the heart rate was reduced by a mean of 13.8 and 16.6 beats per minute in the 1.25-mg and 5.0-mg groups, respectively, returning toward the baseline value with continued treatment. Symptomatic bradycardia was reported in one patient who received fingolimod at a dose of 1.25 mg after switching from placebo and in three patients who received fingolimod at a dose of 5.0 mg; no cases of symptomatic bradycardia were reported among patients who received placebo. All episodes occurred within 24 hours after administration of the first dose and resolved spontaneously. Holter electrocardiographic monitoring was performed in 31 patients who received placebo, 31 patients who received fingolimod at a dose of 1.25 mg, and 34 patients who received fingolimod at a dose of 5.0 mg. These assessments confirmed that the maximal decrease in the heart rate in the patients treated with fingolimod, as compared with those who received placebo, occurred within the first 6 hours. Transient second-degree Wenckebach atrioventricular block occurred in four patients who received fingolimod at a dose of 1.25 mg (in one patient only at baseline, in one at baseline and day 1, and in two on day 1) and five patients who received fingolimod at a dose of 5.0 mg (all on day 1). All Holter assessments at 3 months were normal in the patients who received placebo and in those who received fingolimod at a dose of 1.25 mg; a single episode of nonsustained ventricular tachycardia (four beats) was reported on one tracing in a patient who received fingolimod at a dose of 5.0 mg. There was an initial reduction in mean blood pressure (5 to 6 mm Hg lower than the baseline value) within 4 to 5 hours after the administration of fingolimod, followed by a sustained elevation (4 to 6 mm Hg higher than the baseline value) after 2 months of treatment, with no further increase during the extension study (data not shown).
During the core study, pulmonary-function tests showed a reduction in FEV1 in the group of patients who received fingolimod at a dose of 5.0 mg, as compared with the placebo group. The average reduction from baseline in the percentage of predicted FEV1 at month 6 was 1.9% in the placebo group (37 patients), as compared with 8.8% (P=0.003) in the group of patients who received fingolimod at a dose of 5.0 mg (35 patients) and 2.8% (P=0.68) in the group of patients who received fingolimod at a dose of 1.25 mg (40 patients). After 6 months of treatment, as compared with an increase of 4.3% of the predicted FVC in the placebo group, the FVC was decreased by 0.8% in the group of patients who received fingolimod at a dose of 1.25 mg and by 3.2% of the predicted value in the group of patients who received fingolimod at a dose of 5.0 mg (P<0.05 for both comparisons with placebo). In both groups of patients who received fingolimod, the carbon monoxide diffusion capacity did not differ from that in the patients who received placebo. In the extension study, there was no further change in FEV1, FVC, or the carbon monoxide diffusion capacity at month 12, as compared with month 6, in any of the groups (those who received continuous fingolimod or those who switched from placebo to fingolimod; data not shown). No increase in clinical respiratory adverse events was reported in the group of patients who received fingolimod at a dose of 1.25 mg, as compared with the placebo group. There were more reports of dyspnea in the group of patients who received fingolimod at a dose of 5.0 mg than in the placebo group (Table 4). During the extension study, dyspnea was rarely reported (no reports in the group of patients who received continuous treatment with fingolimod at a dose of 1.25 mg and one report each in the other three groups).
Discussion
Our results demonstrate that oral fingolimod given once daily provides significant and rapid improvement in MRI measures of inflammation and in relapse-related clinical end points in patients with relapsing multiple sclerosis. Patients who received placebo also had marked improvements after switching to the active drug in the extension study.
These clinical and MRI results suggest that the main mechanism of action of fingolimod — sequestration of lymphocytes in secondary lymphoid organs through an interaction with G protein–coupled receptors for sphingosine-1-phosphate15 — has a favorable effect on the course of relapsing multiple sclerosis. Additional mechanisms may also be involved. These mechanisms may be related to binding to other sphingosine-1-phosphate receptors — also expressed in neural cells33-36 — and to the high availability of fingolimod within the central nervous system because of its lipophilic nature. The observation that the 1.25-mg dose was as effective as the 5.0-mg dose, in terms of both MRI findings and relapse rates, provides evidence of a need to explore the effects of a lower dose in future trials.
The most frequently reported adverse events associated with fingolimod were upper respiratory tract infections (mainly nasopharyngitis). Two serious infections were reported in patients who were given fingolimod, and larger trials are needed for a full assessment of the risk of serious infections with fingolimod therapy. Similarly, the risk of the posterior reversible encephalopathy syndrome needs to be quantified; in our study it occurred in one patient who was given fingolimod. The pathogenesis of this syndrome is unclear but seems to be related to impaired autoregulation and endothelial function. It has been associated with hypertension, eclampsia, and the use of several immunosuppressive and immunomodulating agents, including interferon alfa and immune globulins administered intravenously.31,32
The importance of elevated liver enzyme levels observed in this study requires further evaluation in longer-term studies. Liver enzyme abnormalities were not found in transplantation studies. In these studies, fingolimod was administered as an add-on therapy to cyclosporine,37 and its hepatic effects may therefore have been disguised by concomitant treatment with this agent, which is known to cause elevated aminotransferase levels. The dose-dependent decline in the heart rate observed in the first hours after the first dose has also been reported in studies of transplantation.37-39 We observed other adverse events related to the pharmacologic characteristics of fingolimod, including decreases in forced expiratory flow and increases in respiratory symptoms and blood pressure.
Our results show that oral fingolimod may be a treatment option for relapsing multiple sclerosis. Before these findings can be considered clinically directive, the benefits and risks of fingolimod need to be further evaluated in larger-scale, longer-term clinical studies.
Supported by Novartis Pharma, Basel, Switzerland.
Dr. Kappos reports having participated as principal investigator, member, or chair of planning and steering committees or advisory boards in clinical trials of multiple sclerosis sponsored by Abbott, Bayer, Bayhill, Berlex, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Centocor, Eisai, Elan, Genzyme, GlaxoSmithKline, Immune Response, Neurocrine, Novartis, Sanofi-Aventis, Schering, Serono, Roche, Teva, UCB Pharma, and Wyeth and having received lecture fees from one or more of the above-listed companies. Dr. Antel reports having received remuneration for consulting, participation in clinical trials, and advisory board and steering committee membership from Aegera, Aventis, Bayhill, Berlex, Biogen Idec, BioMS, Boehringer Ingelheim, Genentech, Immune Response, Neurocrine Biosciences, Novartis, Schering-Plough, Serono, and Teva Neuroscience. Dr. Comi reports having received consulting fees from Serono, Schering, Teva, Novartis, Sanofi-Aventis, Biogen and Wyeth; grant support from Teva and Serono; and lecture fees from Teva, Serono, and Schering. Dr. Radue reports having received grant support and lecture fees from Biogen Idec, Schering, Novartis, Sanofi-Aventis, and GlaxoSmithKline for evaluation of multicenter studies of multiple sclerosis, as well as payments for advisory-board and steering-committee membership. Dr. Montalban reports having received consulting fees from Biogen Idec, Sanofi-Aventis, Novartis, Serono, Schering, and Wyeth; lecture fees from Biogen, Schering, Sanofi-Aventis and Serono; and grant support from Biogen Idec, Sanofi-Aventis, Serono and Schering. Dr. O'Connor reports having received consulting fees from Biogen Idec, Bristol-Myers Squibb, Sanofi-Aventis, Novartis, Serono, Schering, and Wyeth; lecture fees from Biogen Idec; and grant support from Biogen Idec, Novartis, Sanofi-Aventis, Schering, BioMS, Bristol-Myers Squibb, and Genentech. Dr. Polman reports having received consulting fees from Biogen Idec, Schering, Teva, Serono, Novartis, GlaxoSmithKline, and Antisense Therapeutics; lecture fees from Biogen Idec, Schering, and Teva; and grant support from Biogen Idec, Schering, Wyeth, and GlaxoSmithKline. Drs. Haas, Korn, and Karlsson are employees of Novartis; Drs. Korn and Karlsson report owning shares in Novartis. No other potential conflict of interest relevant to this article was reported.
Source Information
From the Departments of Neurology and Research, University Hospital, Basel, Switzerland (L.K.); Le Centre Universitaire de Santé McGill, Montreal Neurological Institute, McGill University, Montreal (J.A.); Neurology Clinic, San Raffaele Hospital, University Vita e Salute, Milan (G.C.); Neuroimmunology Unit, Hospital Vall d'Hebron, Barcelona (X.M.); Division of Neurology, St. Michael's Hospital, Toronto (P.O.); Department of Neurology, Vrije Universiteit Medical Center, Amsterdam (C.H.P.); Biostatistics and Statistical Reporting (T.H.) and Clinical Development and Medical Affairs (G.K.), Novartis Pharma, Basel, Switzerland; Clinical Development and Medical Affairs, Novartis Pharmaceuticals, East Hanover, NJ (A.A.K.); and Neuroradiology and MS-MRI Evaluation Center, University Hospital, Basel, Switzerland (E.W.R.).
Address reprint requests to Dr. Kappos at the Departments of Neurology and Research, University Hospital, Petersgraben 4, 4031 Basel, Switzerland, or at lkappos@uhbs.ch.
The members of the FTY720 D2201 Study Group are listed in the Appendix.
Appendix
The following people participated in the study (names of principal investigators are in bold): Data and Safety Monitoring Board — C. Polman (chair), Vrije Universiteit Medical Center, Amsterdam; J. Camm, St. George's Hospital Medical School, London; M. Daumer, Sylvia Lawry Centre for Multiple Sclerosis Research, Munich; F. Lublin, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, New York; Steering Committee — L. Kappos (chair), University Hospital, Basel; J. Antel, Le Centre Universitaire de Santé McGill, Montreal Neurological Institute, McGill University, Montreal; G. Comi, San Raffaele Hospital, Milan; A. Korn, Novartis Pharmaceuticals Corporation, East Hanover, NJ; X. Montalban, Hospital Vall d'Hebron, Barcelona; P. O'Connor, St. Michael's Hospital, Toronto; E.W. Radue, University Hospital, Basel; Study Group — Canada: J. Antel, L. Durcan, A. Baror, Le Centre Universitaire de Santé McGill, Montreal Neurological Institute, McGill University, Montreal; P. Duquette, G. Bernier, Centre Hospitalier Universitaire–Notre-Dame Hospital, Montreal; M. Freedman, H. MacLean, F. Costello, Ottawa Hospital, Ottawa; P. O'Connor, T.A. Gray, M. Hohol, St. Michael's Hospital, Toronto; J. Oger, S. Hashimoto, V. Devonshire, UBC Hospital, Vancouver; Denmark: P.S.G. Sørensen, P. Datta, J.C. Faber-Rod, Neurocentret, Rigshospitalet, Copenhagen; J. Frederiksen, S. Knudsen, V. Petrenaite, Kobenhavns Amts Sygehus, Glostrup; Finland: M. Färkkila, J. Halavaara, H. Harno, Postitalon Lääkäriasema Oy, Helsinki; I. Elovaara, H. Kuusisto, J. Palmio, Finn-Medi Tutkimus Oy, Tampere; L. Airas, V. Kaasinen, M. Laaksonen, Turku University Hospital, Turku; France: P. Vermersch, Hôpital Roger Salengro, Lille; J. Pelletier, L. Feuillet, L. Suchet, Hôpital de la Timone, Marseille; Germany: E. Mauch, C. Gunser, K. Oberbeck, Akademisches KH der Universität Ulm, Schwendi; P. Rieckmann, M. Buttmann, M. Klein, Julius-Maximilians-Universität, Würzburg; Italy: A. Ghezzi, M. Zaffaroni, S. Baldini, Ospedale S. Antonio Abate, Gallarate; G. Mancardi, F. Cioli, E. Capello, Ospedale S. Martino Università degli Studi di Genova, Genoa; G. Comi, L. Maiola, F. Esposito, San Raffaele Hospital, Milan; C. Pozzilli, E. Onesti, S. Romano, Ospedale Sant'Andrea Università La Sapienza, Rome; Poland : A. Czlonkowska, T. Litwin, L. Darda-Ledzion, Instytut Psychiatrii i Neurologii, Warsaw; H. Kwiecinksi, M. Golebiowski, A. Podlecka, Klinika Neurologii AM, Warsaw; Portugal: L. Cunha, F. Matias, M. do Carmo Macario, Hospitais da Universidade de Coimbra, Coimbra; R. Pedrosa, M. Almeida, J. Esteves Pena, Hospital Sto. António dos Capuchos, Lisbon; J. de Sa, J. Buerra da Costa, J. Ferreira, Hospital de Santa Maria, Centro de estudos Egas Moniz, Lisbon; Spain: T. Arbizu, O. Carmona, V. Casado, Ciutat Sanitària i Universitària de Bellvitge, Barcelona; X. Montalban, M. Tintore, R. Pelayo, Hospital Vall d'Hebron, Barcelona; R. Arroyo, M. Bartolome, V. De las Heras, Hospital Clinico San Carlos, Madrid; B. Casanova, I. Bosca, Hospital La Fe, Valencia; O. Fernandez, A. Leon, F. Romero, Hospital Carlos Haya, Malaga; G. Izquierdo, M. Gamero, J. Maria Garcia, Hospital Virgen de la Macarena, Seville; Switzerland: L. Kappos, J. Kuhle, L. Achtnichts, University Hospital, Basel; N. Goebels, C. Skulina, J. Waskoenig, University Hospital, Zurich; United Kingdom: D. Bates, P. Nichols, Royal Victoria Infirmary, Newcastle-upon-Tyne; MS–MRI Evaluation Center: University Hospital, Basel; E.W. Radue, A. de Vera, Novartis Pharma, Basel, Switzerland, and East Hanover, NJ: O. Bettoni-Ristic, P. Burtin, R. Preiss, S. Wehr, T. Zubal.
- References
References
1
Noseworthy JH ,Lucchinetti CF ,Rodriguez M ,Weinshenker BG . Multiple sclerosis. N Engl J Med 2000;343:938-952
Full Text | Web of Science | Medline2
Compston A ,Coles A . Multiple sclerosis. Lancet 2002;359:1221-1231[Erratum, Lancet 2002;360:648.]
CrossRef | Web of Science | Medline3
Sospedra M ,Martin R . Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747
CrossRef | Web of Science | Medline4
Trapp BD ,Peterson J ,Ransohoff RM ,Rudick R ,Mork S ,Bo L . Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285
Full Text | Web of Science | Medline5
The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group
Web of Science | Medline6
Jacobs LD ,Cookfair DL ,Rudick RA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294[Erratum, Ann Neurol 1996;40:480.]
CrossRef | Web of Science | Medline7
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group
CrossRef | Web of Science | Medline8
Johnson KP ,Brooks BR ,Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276
Web of Science | Medline9
Goodin DS ,Frohman EM ,Garmany GP Jr , et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178[Erratum, Neurology 2002;59:480.]
Web of Science | Medline10
Galetta SL ,Markowitz C . US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs 2005;19:239-252
CrossRef | Web of Science | Medline11
Calabresi PA . Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology 2002;58:Suppl 4:S10-S22
Web of Science | Medline12
Brinkmann V ,Davis MD ,Heise CE , et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277:21453-21457
CrossRef | Web of Science | Medline13
Mandala S ,Hajdu R ,Bergstrom J , et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-349
CrossRef | Web of Science | Medline14
Brinkmann V ,Cyster JG ,Hla T . FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4:1019-1025
CrossRef | Web of Science | Medline15
Matloubian M ,Lo CG ,Cinamon G , et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-360
CrossRef | Web of Science | Medline16
Pinschewer DD ,Ochsenbein AF ,Odermatt B ,Brinkmann V ,Hengartner H ,Zinkernagel RM . FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000;164:5761-5770
Web of Science | Medline17
Webb M ,Tham C-S ,Lin F-F , et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004;153:108-121
CrossRef | Web of Science | Medline18
Fujino M ,Funeshima N ,Kitazawa Y , et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003;305:70-77
CrossRef | Web of Science | Medline19
McDonald WI ,Compston A ,Edan G , et al. Recommended diagnosis criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127
CrossRef | Web of Science | Medline20
Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
Web of Science | Medline21
ICH harmonized tripartite guidelines for good clinical practice: E6(R1). June 10, 1996. (Accessed August 18, 2006, at http://www.ich.org/LOB/media/MEDIA482.pdf.)
22
World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. (Accessed August 18, 2006, at http://www.wma.net/e/policy/b3.htm.)
23
Miller DH ,Barkhof F ,Berry I ,Kappos L ,Scotti G ,Thompson AJ . Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688
CrossRef | Web of Science | Medline24
McFarland HF ,Barkhof F ,Antel J ,Miller DH . The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002;8:40-51
Web of Science | Medline25
Evaluation Center Basel, Mercury Computer Systems GmbH. Interactive segmentation program, developed on the AMIRA platform: MS-MRI. (Accessed August 18, 2006, at http://www.amiravis.com.)
26
Smith SM ,Zhang Y ,Jenkinson M , et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-489
CrossRef | Web of Science | Medline27
Kappos L, Lechner-Scott J, Lienert C. Neurostatus training and documentation CD-ROM for a standardized neurological examination and assessment of Kurtzke's functional systems and expanded disability status scale for MS patients. Basel, Switzerland: Point de Vue Audiovisuelle Produktionen, 2003. (Accessed August 18, 2006, at http://www.neurostatus.net/training/training.php.)
28
Sylvia Lawry Centre for Multiple Sclerosis Research. Home page. Munich, Germany. (Accessed August 18, 2006, at http://www.slcmsr.info/en/index.htm.)
29
Nauta JJ ,Thompson AJ ,Barkhof F ,Miller DH . Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 1994;122:6-14
CrossRef | Web of Science | Medline30
Hardin JW, Hilbe JM. Generalized estimating equations. Boca Raton, FL: Chapman & Hall/CRC Press, 2003.
31
Stott VL ,Hurrell MA ,Anderson TJ . Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J 2005;35:83-90
CrossRef | Web of Science | Medline32
Lamy C ,Oppenheim C ,Meder JF ,Mas JL . Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging 2004;14:89-96
CrossRef | Web of Science | Medline33
Rao TS ,Lariosa-Willingham KD ,Lin FF , et al. Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res 2003;990:182-194
CrossRef | Web of Science | Medline34
Tham CS ,Lin FF ,Rao TS ,Yu N ,Webb M . Microglial activation state and lysophospholipid acid receptor expression. Int J Dev Neurosci 2003;21:431-443
CrossRef | Web of Science | Medline35
Toman RE ,Payne SG ,Watterson KR , et al. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 2004;166:381-392
CrossRef | Web of Science | Medline36
Yu N ,Lariosa-Willingham KD ,Lin FF ,Webb M ,Rao TS . Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia 2004;45:17-27
CrossRef | Web of Science | Medline37
Tedesco-Silva H ,Mourad G ,Kahan BD , et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005;79:1553-1560
CrossRef | Web of Science | Medline38
Jardine A ,Grinyo JM ,Mulgaonkar S , et al. FTY720, a sphingosine 1 phosphate receptor agonist, does not elicit adverse effects on cardiac rhythm in renal transplant patients on maintenance therapy. Am J Transplant 2004;4:Suppl 8:443-443
CrossRef | Web of Science39
Koyrakh L ,Roman MI ,Brinkmann V ,Wickman K . The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005;5:529-536
CrossRef | Web of Science | Medline
- Citing Articles (258)
Citing Articles
1
Pelletier, Daniel, Hafler, David A., . (2012) Fingolimod for Multiple Sclerosis. New England Journal of Medicine 366:4, 339-347
Full Text2
Olivier J. David, John M. Kovarik, Robert L. Schmouder. (2012) Clinical Pharmacokinetics of Fingolimod. Clinical Pharmacokinetics 51:1, 15-28
CrossRef3
N. Ferreirós, S. Labocha, M. Schröder, H.H. Radeke, G. Geisslinger. (2012) LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma. Journal of Chromatography B
CrossRef4
Shiv Saidha, Christopher Eckstein, Peter A. Calabresi. (2012) New and emerging disease modifying therapies for multiple sclerosis. Annals of the New York Academy of Sciencesno-no
CrossRef5
Kerstin Bendfeldt, Stefan Klöppel, Thomas E. Nichols, Renata Smieskova, Pascal Kuster, Stefan Traud, Nicole Mueller-Lenke, Yvonne Naegelin, Ludwig Kappos, Ernst-Wilhelm Radue, Stefan J. Borgwardt. (2012) Multivariate pattern classification of gray matter pathology in multiple sclerosis. NeuroImage
CrossRef6
Claudio Gasperini, Serena Ruggieri. (2011) Emerging oral drugs for relapsing–remitting multiple sclerosis. Expert Opinion on Emerging Drugs1-16
CrossRef7
Frederik Barkhof, Jack H. Simon, Franz Fazekas, Marco Rovaris, Ludwig Kappos, Nicola de Stefano, Chris H. Polman, John Petkau, Ernst W. Radue, Maria P. Sormani, David K. Li, Paul O'Connor, Xavier Montalban, David H. Miller, Massimo Filippi. (2011) MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nature Reviews Neurology
CrossRef8
Assaf Marcus, Zelig Eshhar. (2011) Tumor-specific allogeneic cells for cancer therapy. Expert Opinion on Biological Therapy 11:12, 1551-1554
CrossRef9
Robert Schmouder, Sam Hariry, Olivier J. David. (2011) Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. European Journal of Clinical Pharmacology
CrossRef10
I. J. van den Elskamp, D. L. Knol, B. M. J. Uitdehaag, F. Barkhof. (2011) Modeling MR Imaging Enhancing-Lesion Volumes in Multiple Sclerosis: Application in Clinical Trials. American Journal of Neuroradiology
CrossRef11
Joep Killestein, Richard A Rudick, Chris H Polman. (2011) Oral treatment for multiple sclerosis. The Lancet Neurology 10:11, 1026-1034
CrossRef12
Oscar Fernández. (2011) Nuevos fármacos para el tratamiento de la esclerosis múltiple. FMC - Formación Médica Continuada en Atención Primaria 18:9, 582-588
CrossRef13
Yossan
Var Tan, James A Waschek. (2011) Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. ASN NEURO 3:4, 195-212
CrossRef14
Takashi Yoshino, Hiroko Tabunoki, Shigeo Sugiyama, Keitaro Ishii, Seung U. Kim, Jun-ichi Satoh. (2011) Non-phosphorylated FTY720 Induces Apoptosis of Human Microglia by Activating SREBP2. Cellular and Molecular Neurobiology 31:7, 1009-1020
CrossRef15
Rebecca Spain, Dennis Bourdette. (2011) The Radiologically Isolated Syndrome: Look (Again) Before You Treat. Current Neurology and Neuroscience Reports 11:5, 498-506
CrossRef16
Ludwig Kappos, David Li, Peter A Calabresi, Paul O'Connor, Amit Bar-Or, Frederik Barkhof, Ming Yin, David Leppert, Robert Glanzman, Jeroen Tinbergen, Stephen L Hauser. (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. The Lancet
CrossRef17
Kazuki Morohoshi, Michiko Osone, Katsumi Yoshida, Yoshinori Nakagawa, Saeko Hoshikawa, Hiroshi Ozaki, Yurie Takahashi, Sadayoshi Ito, Kouki Mori. (2011) The sphingosine 1-phosphate receptor modulator FTY720 prevents iodide-induced autoimmune thyroiditis in non-obese diabetic mice. Autoimmunity 44:6, 490-495
CrossRef18
Yinghui Hu, Xinhua Lee, Benxiu Ji, Kevin Guckian, Daniel Apicco, R. Blake Pepinsky, Robert H. Miller, Sha Mi. (2011) Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo. Molecular and Cellular Neuroscience 48:1, 72-81
CrossRef19
Roberto Gallego-Pinazo, Enrique España-Gregori, Diamar Pardo-López, Manuel Díaz-Llopis, Enrique España-Gregori, Bonaventura Casanova, Manuel Díaz-Llopis. (2011) Branch Retinal Vein Occlusion During Fingolimod Treatment in a Patient With Multiple Sclerosis. Journal of Neuro-Ophthalmology 31:3, 292-293
CrossRef20
Daniel Ontaneda, Jeffrey A Cohen. (2011) Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Review of Clinical Pharmacology 4:5, 567-570
CrossRef21
Manshu Sui, Jin Zhou, Rujuan Xie, Xiaogang Liu, Suhong Mu, Xibei Jia, Jing Ma, Hongchi Wu. (2011) The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis. Molecular Biology Reports
CrossRef22
Laura M. Tormoehlen. (2011) Toxic Leukoencephalopathies. Neurologic Clinics 29:3, 591-605
CrossRef23
Holger Christian Müller, Andreas Christian Hocke, Katharina Hellwig, Birgitt Gutbier, Harm Peters, Stefanie Maria Schönrock, Thomas Tschernig, Andreas Schmiedl, Stefan Hippenstiel, Philippe Dje N’Guessan, Simone Rosseau, Norbert Suttorp, Martin Witzenrath. (2011) The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice. Pulmonary Pharmacology & Therapeutics 24:4, 377-385
CrossRef24
Lesley J. Scott. (2011) Fingolimod. CNS Drugs 25:8, 673-698
CrossRef25
A. Marcus, T. Waks, Z. Eshhar. (2011) Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood 118:4, 975-983
CrossRef26
Mirjam Schuchardt, Markus Tölle, Jasmin Prüfer, Markus van der Giet. (2011) Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system. British Journal of Pharmacology 163:6, 1140-1162
CrossRef27
Junichi Kikuta, Kaori Iwai, Yukihiko Saeki, Masaru Ishii. (2011) S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis. Rheumatology International 31:7, 967-969
CrossRef28
Emmanuel H. Demont, Benjamin I. Andrews, Rino A. Bit, Colin A. Campbell, Jason W. B. Cooke, Nigel Deeks, Sapna Desai, Simon J. Dowell, Pam Gaskin, James R. J. Gray, Andrea Haynes, Duncan S. Holmes, Umesh Kumar, Mary A. Morse, Greg J. Osborne, Terry Panchal, Bela Patel, Alcide Perboni, Simon Taylor, Robert Watson, Jason Witherington, Robert Willis. (2011) Discovery of a Selective S1P 1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate. ACS Medicinal Chemistry Letters 2:6, 444-449
CrossRef29
Philip M. Yangyuoru, Antony C. Otieno, Simon M. Mwongela. (2011) Determination of sphingosine kinase 2 activity using fluorescent sphingosine by capillary electrophoresis. ELECTROPHORESIS 32:13, 1742-1749
CrossRef30
Bhupendra Khatri, Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Xavier Montalban, Jean Pelletier, Tracy Stites, Stacy Wu, Fred Holdbrook, Lixin Zhang-Auberson, Gordon Francis, Jeffrey A Cohen. (2011) Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology 10:6, 520-529
CrossRef31
Z.-Y. Zhang, C. Zug, H. J. Schluesener. (2011) Sphingosine 1-Phosphate Receptor Modulator FTY720 Suppresses Rat Experimental Autoimmune Prostatitis. Scandinavian Journal of Immunology 73:6, 546-553
CrossRef32
Hans-Peter Hartung, Helmar C. Lehmann, Bernd C. Kieseier, Richard A. C. Hughes. (2011) Novel treatment for immune neuropathies on the horizon. Journal of the Peripheral Nervous System 16:2, 75-83
CrossRef33
Myat Lin Oo, Sung-Hee Chang, Shobha Thangada, Ming-Tao Wu, Karim Rezaul, Victoria Blaho, Sun-Il Hwang, David K. Han, Timothy Hla. (2011) Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. Journal of Clinical Investigation 121:6, 2290-2300
CrossRef34
Bernd C Kieseier, Heinz Wiendl. (2011) Transforming multiple sclerosis trials into practical reality. The Lancet Neurology 10:6, 493-494
CrossRef35
Naser Muja, Mikhal E. Cohen, Jiangyang Zhang, Heechul Kim, Assaf A. Gilad, Piotr Walczak, Tamir Ben-Hur, Jeff W.M. Bulte. (2011) Neural precursors exhibit distinctly different patterns of cell migration upon transplantation during either the acute or chronic phase of EAE: A serial MR imaging study. Magnetic Resonance in Medicine 65:6, 1738-1749
CrossRef36
Takahide Nishi, Shojiro Miyazaki, Toshiyasu Takemoto, Keisuke Suzuki, Yukiko Iio, Katsuyoshi Nakajima, Takashi Ohnuki, Yumi Kawase, Futoshi Nara, Shinichi Inaba, Takashi Izumi, Hiroshi Yuita, Keiko Oshima, Hiromi Doi, Ryotaku Inoue, Wataru Tomisato, Takashi Kagari, Takaichi Shimozato. (2011) Discovery of CS-0777: A Potent, Selective, and Orally Active S1P 1 Agonist. ACS Medicinal Chemistry Letters 2:5, 368-372
CrossRef37
Adil Javed, Betty Soliven. (2011) Fingolimod: a novel oral immunomodulatory treatment for multiple sclerosis. Future Neurology 6:3, 315-325
CrossRef38
Jeffrey A. Cohen, Jerold Chun. (2011) Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Annals of Neurology 69:5, 759-777
CrossRef39
Martin Duddy, Aiden Haghikia, Eleonora Cocco, Christian Eggers, Jelena Drulovic, Olga Carmona, Helene Zéphir, Ralf Gold. (2011) Managing MS in a changing treatment landscape. Journal of Neurology 258:5, 728-739
CrossRef40
Jens Ingwersen, Orhan Aktas, Patrick Kuery, Bernd Kieseier, Alexey Boyko, Hans-Peter Hartung. (2011) Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy. Clinical Immunology
CrossRef41
Christian R. Rau, Katharina Hein, Muriel B. Sättler, Benedikt Kretzschmar, Carina Hillgruber, Bradford L. McRae, Ricarda Diem, Mathias Bähr. (2011) Anti-Inflammatory Effects of FTY720 Do Not Prevent Neuronal Cell Loss in a Rat Model of Optic Neuritis. The American Journal of Pathology 178:4, 1770-1781
CrossRef42
E. Ann Yeh, B. Weinstock-Guttman. (2011) Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis. Advances in Therapy 28:4, 270-278
CrossRef43
Kenji Chiba, Hirotoshi Kataoka, Noriyasu Seki, Kyoko Shimano, Mamoru Koyama, Atsushi Fukunari, Kunio Sugahara, Takahisa Sugita. (2011) Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis. International Immunopharmacology 11:3, 366-372
CrossRef44
Yoshitaka Sogawa, Takao Ohyama, Hiroaki Maeda, Kazuki Hirahara. (2011) Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: indication of cross-desensitization in vivo. Immunology 132:3, 441-450
CrossRef45
O. Aktas, J. Ingwersen, B. Kieseier, P. Küry, R. Hohlfeld, H.-P. Hartung. (2011) Orales Fingolimod bei Multipler Sklerose. Der Nervenarzt 82:2, 215-225
CrossRef46
Jacek Losy, Alicja Kalinowska-Łyszczarz. (2011) Emerging disease-modifying oral therapies for multiple sclerosis. Journal of Neuroimmunology 231:1-2, 15-22
CrossRef47
Jennifer M. Belavic. (2011) Annual Drug Update. The Nurse Practitioner 36:2, 10-22
CrossRef48
Maciej Malinowski, Peter Martus, Johan Friso Lock, Peter Neuhaus, Martin Stockmann. (2011) Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function. Transplant International 24:2, 184-193
CrossRef49
Douglas R Jeffery, Clyde E Markowitz, Anthony T Reder, Bianca Weinstock-Guttman, Kathy Tobias. (2011) Fingolimod for the treatment of relapsing multiple sclerosis. Expert Review of Neurotherapeutics 11:2, 165-183
CrossRef50
Matthias Mehling, Patricia Hilbert, Stefanie Fritz, Bojana Durovic, Dominik Eichin, Olivier Gasser, Jens Kuhle, Thomas Klimkait, Raija L.P. Lindberg, Ludwig Kappos, Christoph Hess. (2011) Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Annals of Neurology 69:2, 408-413
CrossRef51
Colleen E. Miller, Margaret A. Umhauer. (2011) Emerging Oral Therapies for Multiple Sclerosis. Journal of Neuroscience Nursing 43:1, 3-14
CrossRef52
Dennis J. Cada, Terri L. Levien, Danial E. Baker. (2011) Formulary Drug Reviews - Fingolimod. Hospital Pharmacy 46:2, 122-129
CrossRef53
Jeffrey A. Cohen. (2011) Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics. Annual Review of Medicine 63:1, 110301100719093
CrossRef54
Glyn Dawson, Jingdong Qin. (2011) Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants. Biochemical and Biophysical Research Communications 404:1, 321-323
CrossRef55
Ralf Gold. (2011) Oral Therapies for Multiple Sclerosis. CNS Drugs 25:1, 37-52
CrossRef56
Kenji Chiba, Hirotoshi Kataoka, Noriyasu Seki, Yasuhiro Maeda, Kunio Sugahara. (2011) Fingolimod (FTY720), the Sphingosine 1-Phosphate Receptor Modulator, as a New Therapeutic Drug in Multiple Sclerosis. Inflammation and Regeneration 31:2, 167-174
CrossRef57
Kunitomo Adachi. (2011) FTY720 Story: Discovery of the First Sphingosine 1-Phosphate Receptor Modulator. Journal of Synthetic Organic Chemistry, Japan 69:8, 904-912
CrossRef58
Tsuyoshi Iwasaki, Sachi Tsunemi, Sachie Kitano, Chieri Kanda, Masahiro Sekiguchi, Masayasu Kitano, Hajime Sano. (2011) Role of sphingosine 1-phosphate signaling for the pathogenesis of autoimmune diseases. Inflammation and Regeneration 31:2, 175-183
CrossRef59
Kerstin Bendfeldt, Louis Hofstetter, Pascal Kuster, Stefan Traud, Nicole Mueller-Lenke, Yvonne Naegelin, Ludwig Kappos, Achim Gass, Thomas E. Nichols, Frederik Barkhof, Hugo Vrenken, Stefan D. Roosendaal, Jeroen J.G. Geurts, Ernst-Wilhelm Radue, Stefan J. Borgwardt. (2011) Longitudinal gray matter changes in multiple sclerosis-Differential scanner and overall disease-related effects. Human Brain Mappingn/a-n/a
CrossRef60
Samuel J Jackson, Gavin Giovannoni, David Baker. (2011) Fingolimod modulates microglial activation to augment markers of remyelination. Journal of Neuroinflammation 8:1, 76
CrossRef61
Sachi Tsunemi, Tsuyoshi Iwasaki, Keiji Miyazawa, Sachie Kitano, Chieri Kanda, Harunori Takeshita, Masahiro Sekiguchi, Masayasu Kitano, Hajime Sano. (2011) Therapy of autoimmune diseases by novel immunosuppressant FTY720. Inflammation and Regeneration 31:3, 307-315
CrossRef62
Yuya Yoshida, Takumi Tsuji, Tetsuro Fujita, Takeyuki Kohno. (2011) Relapse of Experimental Autoimmune Encephalomyelitis after Discontinuation of FTY720 (Fingolimod) Treatment, but Not after Combination of FTY720 and Pathogenic Autoantigen. Biological & Pharmaceutical Bulletin 34:6, 933-936
CrossRef63
Trygve Holmøy, Elisabeth Celius. (2011) Utvikling av ny behandling for multippel sklerose. Tidsskrift for Den norske legeforening 131:8, 832-836
CrossRef64
Arundhati Jana, Kalipada Pahan. (2010) Sphingolipids in Multiple Sclerosis. NeuroMolecular Medicine 12:4, 351-361
CrossRef65
Amy Perrin Ross, Ben W. Thrower. (2010) Recent Developments in the Early Diagnosis and Management of Multiple Sclerosis. Journal of Neuroscience Nursing 42:6, 342-353
CrossRef66
Jay Requarth. (2010) Regarding “A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency”. Journal of Vascular Surgery 52:6, 1748
CrossRef67
Eilhard Mix, Hans Meyer-Rienecker, Hans-Peter Hartung, Uwe K. Zettl. (2010) Animal models of multiple sclerosis—Potentials and limitations. Progress in Neurobiology 92:3, 386-404
CrossRef68
Volker Brinkmann, Andreas Billich, Thomas Baumruker, Peter Heining, Robert Schmouder, Gordon Francis, Shreeram Aradhye, Pascale Burtin. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature Reviews Drug Discovery 9:11, 883-897
CrossRef69
M. Filippi, M. A. Rocca, D. L. Arnold, R. Bakshi, F. Barkhof, N. De Stefano, F. Fazekas, E. Frohman, D. H. Miller, J. S. Wolinsky. 2010. Use of Imaging in Multiple Sclerosis. , 35-51.
CrossRef70
Tomoya Ohno, Chihiro Hasegawa, Susumu Nakade, Junsaku Kitagawa, Naoki Honda, Mikio Ogawa. (2010) The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling. Biopharmaceutics & Drug Disposition 31:7, 396-406
CrossRef71
Trina A. Johnson, Igor Shames, Mark Keezer, Yves Lapierre, David G. Haegert, Amit Bar-Or, Jack Antel. (2010) Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clinical Immunology 137:1, 15-20
CrossRef72
Chang Wook Lee, Ji Woong Choi, Jerold Chun. (2010) Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (Fingolimod) in multiple sclerosis. Archives of Pharmacal Research 33:10, 1567-1574
CrossRef73
Kerstin Bendfeldt, Jan Ole Blumhagen, Hanspeter Egger, Patrick Loetscher, Niklaus Denier, Pascal Kuster, Stefan Traud, Nicole Mueller-Lenke, Yvonne Naegelin, Achim Gass, Jochen Hirsch, Ludwig Kappos, Thomas E Nichols, Ernst-Wilhelm Radue, Stefan J. Borgwardt. (2010) Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis. Human Brain Mapping 31:10, 1542-1555
CrossRef74
William J. Pitts. 2010. Immunosuppressive Agents for the Prevention of Transplantation Rejection. .
CrossRef75
David J. Swan, John A. Kirby, Simi Ali. (2010) Vascular biology: the role of sphingosine 1-phosphate in both the resting state and inflammation. Journal of Cellular and Molecular Medicine 14:9, 2211-2222
CrossRef76
Devon Conway, Jeffrey A. Cohen. (2010) Emerging Oral Therapies in Multiple Sclerosis. Current Neurology and Neuroscience Reports 10:5, 381-388
CrossRef77
Tongsen Zheng, Xianzhi Meng, JiaBei Wang, Xi Chen, Dalong Yin, Yingjian Liang, Xuan Song, Shangha Pan, Hongchi Jiang, Lianxin Liu. (2010) PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. Journal of Cellular Biochemistry 111:1, 218-228
CrossRef78
Joanne L. Jones, Alasdair J. Coles. (2010) New treatment strategies in multiple sclerosis. Experimental Neurology 225:1, 34-39
CrossRef79
Lisa M. Connor, Marina C. Harvie, Fenella J. Rich, Kylie M. Quinn, Volker Brinkmann, Graham Le Gros, Joanna R. Kirman. (2010) A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. European Journal of Immunology 40:9, 2482-2492
CrossRef80
Sachi Tsunemi, Tsuyoshi Iwasaki, Sachie Kitano, Takehito Imado, Keiji Miyazawa, Hajime Sano. (2010) Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. Clinical Immunology 136:2, 197-204
CrossRef81
Orhan Aktas, Patrick Küry, Bernd Kieseier, Hans-Peter Hartung. (2010) Fingolimod is a potential novel therapy for multiple sclerosis. Nature Reviews Neurology 6:7, 373-382
CrossRef82
C. Cordiglieri, F. Odoardi, B. Zhang, M. Nebel, N. Kawakami, W. E. F. Klinkert, D. Lodygin, F. Luhder, E. Breunig, D. Schild, V. K. Ulaganathan, K. Dornmair, W. Dammermann, B. V. L. Potter, A. H. Guse, A. Flugel. (2010) Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. Brain 133:7, 1930-1943
CrossRef83
Veronique E. Miron, Samuel K. Ludwin, Peter J. Darlington, Andrew A. Jarjour, Betty Soliven, Timothy E. Kennedy, Jack P. Antel. (2010) Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices. The American Journal of Pathology 176:6, 2682-2694
CrossRef84
Reza Vosoughi, Mark S. Freedman. (2010) Therapy of MS. Clinical Neurology and Neurosurgery 112:5, 365-385
CrossRef85
Ruchika Shaurya Prakash, Erin M. Snook, Robert W. Motl, Arthur F. Kramer. (2010) Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis. Brain Research 1341, 41-51
CrossRef86
Yolanda S. Kap, Jon D. Laman, Bert A. ‘t Hart. (2010) Experimental Autoimmune Encephalomyelitis in the Common Marmoset, a Bridge Between Rodent EAE and Multiple Sclerosis for Immunotherapy Development. Journal of Neuroimmune Pharmacology 5:2, 220-230
CrossRef87
K.- O. Lovblad, N. Anzalone, A. Dorfler, M. Essig, B. Hurwitz, L. Kappos, S.- K. Lee, M. Filippi. (2010) MR Imaging in Multiple Sclerosis: Review and Recommendations for Current Practice. American Journal of Neuroradiology 31:6, 983-989
CrossRef88
Davide Calebiro, Viacheslav O. Nikolaev, Luca Persani, Martin J. Lohse. (2010) Signaling by internalized G-protein-coupled receptors. Trends in Pharmacological Sciences 31:5, 221-228
CrossRef89
L. Steinman. (2010) Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity. Journal of Internal Medicine 267:5, 441-451
CrossRef90
Eva Buehlmann, Gregor E. Berger, Jacqueline Aston, Ute Gschwandtner, Marlon O. Pflueger, Stefan J. Borgwardt, Ernst-Wilhelm Radue, Anita Riecher-Rössler. (2010) Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. Journal of Psychiatric Research 44:7, 447-453
CrossRef91
Mathias Buttmann. (2010) Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Review of Neurotherapeutics 10:5, 791-809
CrossRef92
Bin Ma, Kevin M. Guckian, Edward Yin-Shiang Lin, Wen-Cherng Lee, Daniel Scott, Gnanasambandam Kumaravel, Timothy L. Macdonald, Kevin R. Lynch, Cheryl Black, Sowmya Chollate, Kyungmin Hahm, Gregg Hetu, Ping Jin, Yi Luo, Ellen Rohde, Anthony Rossomando, Robert Scannevin, Joy Wang, Chunhua Yang. (2010) Stereochemistry–activity relationship of orally active tetralin S1P agonist prodrugs. Bioorganic & Medicinal Chemistry Letters 20:7, 2264-2269
CrossRef93
S. Y. Lim, C. S. Constantinescu. (2010) Current and future disease-modifying therapies in multiple sclerosis. International Journal of Clinical Practice 64:5, 637-650
CrossRef94
Seiichiro Ando, Hirofumi Amano, Eri Amano, Kentaro Minowa, Takashi Watanabe, Soichiro Nakano, Yutaka Nakiri, Shinji Morimoto, Yoshiaki Tokano, Qingshun Lin, Rong Hou, Mareki Ohtsuji, Hiromichi Tsurui, Sachiko Hirose, Yoshinari Takasaki. (2010) FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. Biochemical and Biophysical Research Communications 394:3, 804-810
CrossRef95
Kerstin Bendfeldt, Hanspeter Egger, Thomas E. Nichols, Patrick Loetscher, Niklaus Denier, Pascal Kuster, Stefan Traud, Nicole Mueller-Lenke, Yvonne Naegelin, Achim Gass, Ludwig Kappos, Ernst-Wilhelm Radue, Stefan J. Borgwardt. (2010) Effect of immunomodulatory medication on regional gray matter loss in relapsing–remitting multiple sclerosis—A longitudinal MRI study. Brain Research 1325, 174-182
CrossRef96
Jack C Sipe. (2010) Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Expert Review of Neurotherapeutics 10:3, 365-375
CrossRef97
Jerold Chun, Hans-Peter Hartung. (2010) Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis. Clinical Neuropharmacology 33:2, 91-101
CrossRef98
Klemens Högenauer, Klaus Hinterding, Peter Nussbaumer. (2010) S1P receptor mediated activity of FTY720 phosphate mimics. Bioorganic & Medicinal Chemistry Letters 20:5, 1485-1487
CrossRef99
Tom Button, Alasdair J Coles. (2010) Alemtuzumab for the treatment of multiple sclerosis. Future Neurology 5:2, 177-188
CrossRef100
Orhan Aktas, Bernd Kieseier, Hans-Peter Hartung. (2010) Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends in Neurosciences 33:3, 140-152
CrossRef101
Cohen, Jeffrey A., Barkhof, Frederik, Comi, Giancarlo, Hartung, Hans-Peter, Khatri, Bhupendra O., Montalban, Xavier, Pelletier, Jean, Capra, Ruggero, Gallo, Paolo, Izquierdo, Guillermo, Tiel-Wilck, Klaus, de Vera, Ana, Jin, James, Stites, Tracy, Wu, Stacy, Aradhye, Shreeram, Kappos, Ludwig, . (2010) Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine 362:5, 402-415
Full Text102
Kappos, Ludwig, Radue, Ernst-Wilhelm, O'Connor, Paul, Polman, Chris, Hohlfeld, Reinhard, Calabresi, Peter, Selmaj, Krzysztof, Agoropoulou, Catherine, Leyk, Malgorzata, Zhang-Auberson, Lixin, Burtin, Pascale, . (2010) A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. New England Journal of Medicine 362:5, 387-401
Full Text103
Ji Woong Choi, Deron R. Herr, Kyoko Noguchi, Yun C. Yung, Chang-Wook Lee, Tetsuji Mutoh, Mu-En Lin, Siew T. Teo, Kristine E. Park, Alycia N. Mosley, Jerold Chun. (2010) LPA Receptors: Subtypes and Biological Actions. Annual Review of Pharmacology and Toxicology 50:1, 157-186
CrossRef104
Dimitrios Papadopoulos, Jon Rundle, Ryan Patel, Ian Marshall, Jennifer Stretton, Rachel Eaton, Jill C. Richardson, Maria I. Gonzalez, Karen L. Philpott, Richard Reynolds. (2010) FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. Journal of Neuroscience Research 88:2, 346-359
CrossRef105
Setsu Sawai, Hiroshi Umemura, Masahiro Mori, Mamoru Satoh, Sei Hayakawa, Yoshio Kodera, Takeshi Tomonaga, Satoshi Kuwabara, Fumio Nomura. (2010) Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: Proteomic analysis. Journal of Neuroimmunology 218:1-2, 112-115
CrossRef106
Kees Jalink, Wouter H. Moolenaar. (2010) G protein-coupled receptors: the inside story. BioEssays 32:1, 13-16
CrossRef107
Kenji Chiba. (2010) Sphingosine 1-phosphate receptor type 1 as a novel target for the therapy of autoimmune diseases. Inflammation and Regeneration 30:3, 160-168
CrossRef108
Ruben Van Doorn, Jack Van Horssen, Dennis Verzijl, Maarten Witte, Eric Ronken, Bert Van Het Hof, Kim Lakeman, Christine D. Dijkstra, Paul Van Der Valk, Arie Reijerkerk, Astrid E. Alewijnse, Stephan L. M. Peters, Helga E. De Vries. (2010) Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glian/a-n/a
CrossRef109
Kenji Chiba, Hirotoshi Kataoka, Yasuhiro Maeda, Noriyasu Seki, Kunio Sugahara. (2010) Sphingosine 1-phosphate receptor modulator, fingolimod (FTY720), provides a new therapeutic approach for autoimmune diseases. Inflammation and Regeneration 30:5, 419-424
CrossRef110
Tim Friede, Heinz Schmidli. (2010) Blinded sample size reestimation with count data: Methods and applications in multiple sclerosis. Statistics in Medicinen/a-n/a
CrossRef111
Masaaki Niino, Hidenao Sasaki. (2010) Update on the treatment options for multiple sclerosis. Expert Review of Clinical Immunology 6:1, 77-88
CrossRef112
Hirotoshi Kataoka, Kyoko Shimano, Noriyasu Seki, Yasuhiro Maeda, Mamoru Koyama, Atsushi Fukunari, Kunio Sugahara, Takahisa Sugita, Kenji Chiba. (2010) Fingolimod (FTY720) ameliorates experimental autoimmune encephalomyelitis (EAE): I. Oral administration of FTY720 effectively inhibits relapse of EAE. Inflammation and Regeneration 30:5, 451-457
CrossRef113
Scott M. Steward-Tharp, Yun-jeong Song, Richard M. Siegel, John J. O'Shea. (2010) New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Annals of the New York Academy of Sciences 1183:1, 123-148
CrossRef114
R. Klingenberg, G. K. Hansson. (2009) Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. European Heart Journal 30:23, 2838-2844
CrossRef115
Olaf Stüve. (2009) Knowns and unknowns in the future of multiple sclerosis treatment. Journal of the Neurological Sciences 287, S30-S36
CrossRef116
E William St Clair. (2009) Novel targeted therapies for autoimmunity. Current Opinion in Immunology 21:6, 648-657
CrossRef117
Jerry S. Wolinsky, Tzippy Shochat, Sivan Weiss, David Ladkani. (2009) Glatiramer acetate treatment in PPMS: Why males appear to respond favorably. Journal of the Neurological Sciences 286:1-2, 92-98
CrossRef118
Bozena Czech, Waltraud Pfeilschifter, Niloufar Mazaheri-Omrani, Marc André Strobel, Timo Kahles, Tobias Neumann-Haefelin, Abdelhaq Rami, Andrea Huwiler, Josef Pfeilschifter. (2009) The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochemical and Biophysical Research Communications 389:2, 251-256
CrossRef119
Volker Brinkmann. (2009) FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. British Journal of Pharmacology 158:5, 1173-1182
CrossRef120
Yuichiro Ushitora, Hirotaka Tashiro, Takayuki Ogawa, Yoshisato Tanimoto, Shintaro Kuroda, Tsuyoshi Kobayashi, Yoshihiro Miyata, Toshiyuki Itamoto, Toshimasa Asahara, Hideki Ohdan. (2009) Suppression of Hepatocellular Carcinoma Recurrence After Rat Liver Transplantation by FTY720, a Sphingosine-1-Phosphate Analog. Transplantation 88:8, 980-986
CrossRef121
Claudio Gasperini, S. Ruggieri. (2009) New oral drugs for multiple sclerosis. Neurological Sciences 30:S2, 179-183
CrossRef122
Stephen M Anderton. 2009. Immunological Tolerance: Therapeutic Induction. .
CrossRef123
Dong-Soon Im. (2009) New intercellular lipid mediators and their GPCRs: An update. Prostaglandins & Other Lipid Mediators 89:3-4, 53-56
CrossRef124
H. Tedesco-Silva, M.I. Lorber, C.E. Foster, H.W. Sollinger, R. Mendez, D.B. Carvalho, R. Shapiro, P.R. Rajagopalan, H. Mayer, J. Slade, B.D. Kahan, . (2009) FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. Clinical Transplantation 23:5, 589-599
CrossRef125
Manuel A. Friese, Lars Fugger. (2009) Pathogenic CD8 + T cells in multiple sclerosis. Annals of Neurology 66:2, 132-141
CrossRef126
Shannon R. Fix-Stenzel, Martin E. Hayes, Xiaolei Zhang, Grier A. Wallace, Pintipa Grongsaard, Lisa M. Schaffter, Steven M. Hannick, Thaddeus S. Franczyk, Robert H. Stoffel, Kevin P. Cusack. (2009) A stereoselective and scalable synthesis of a conformationally constrained S1P1 agonist. Tetrahedron Letters 50:28, 4081-4083
CrossRef127
P. J. Zhou, H. Wang, G. H. Shi, X. H. Wang, Z. J. Shen, D. Xu. (2009) Immunomodulatory drug FTY720 induces regulatory CD4 + CD25 + T cells in vitro. Clinical & Experimental Immunology 157:1, 40-47
CrossRef128
Takanori Kanai, Yasuhiro Nemoto, Takayuki Tomita, Teruji Totsuka, Mamoru Watanabe, Toshifumi Hibi. (2009) Persistent retention of colitogenic CD4+ memory T cells causes inflammatory bowel diseases to become intractable. Inflammatory Bowel Diseases 15:6, 926-934
CrossRef129
Paul S Giacomini, Peter J Darlington, Amit Bar-Or. (2009) Emerging multiple sclerosis disease-modifying therapies. Current Opinion in Neurology 22:3, 226-232
CrossRef130
Hugh Rosen, Pedro J. Gonzalez-Cabrera, M. Germana Sanna, Steven Brown. (2009) Sphingosine 1-Phosphate Receptor Signaling. Annual Review of Biochemistry 78:1, 743-768
CrossRef131
Frédéric Darios, Catherine Wasser, Anastasia Shakirzyanova, Artur Giniatullin, Kerry Goodman, Jose L. Munoz-Bravo, Jesica Raingo, Jernej Jorgačevski, Marko Kreft, Robert Zorec, Juliana M. Rosa, Luis Gandia, Luis M. Gutiérrez, Thomas Binz, Rashid Giniatullin, Ege T. Kavalali, Bazbek Davletov. (2009) Sphingosine Facilitates SNARE Complex Assembly and Activates Synaptic Vesicle Exocytosis. Neuron 62:5, 683-694
CrossRef132
Florian Mullershausen, Frédéric Zecri, Cihan Cetin, Andreas Billich, Danilo Guerini, Klaus Seuwen. (2009) Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nature Chemical Biology 5:6, 428-434
CrossRef133
Frederik Barkhof, Peter A. Calabresi, David H. Miller, Stephen C. Reingold. (2009) Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nature Reviews Neurology 5:5, 256-266
CrossRef134
Jeffrey L. Bennett, Olaf Stüve. (2009) Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis. Clinical Neuropharmacology 32:3, 121-132
CrossRef135
Bingyi Shi, Zhen Wang, Hailong Jin, Yong Wei Chen, Qiang Wang, Yeyong Qian. (2009) Immunoregulatory Cordyceps sinensis increases regulatory T cells to Th17 cell ratio and delays diabetes in NOD mice. International Immunopharmacology 9:5, 582-586
CrossRef136
J Ludovic Croxford, Takashi Yamamura. (2009) Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies. Immunotherapy 1:3, 403-423
CrossRef137
Melody Ryan. (2009) Drug Therapies for the Treatment of Multiple Sclerosis. Journal of Infusion Nursing 32:3, 137-144
CrossRef138
Joseph R. Berger, Sidney Houff. (2009) Opportunistic infections and other risks with newer multiple sclerosis therapies. Annals of Neurology 65:4, 367-377
CrossRef139
David Marsolais, Hugh Rosen. (2009) Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nature Reviews Drug Discovery 8:4, 297-307
CrossRef140
Carolyn A. Foster, Diana Mechtcheriakova, Maria K. Storch, Balázs Balatoni, Laurence M. Howard, Frédéric Bornancin, Alexander Wlachos, Jury Sobanov, Anu Kinnunen, Thomas Baumruker. (2009) FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood-Brain-Barrier Damage. Brain Pathology 19:2, 254-266
CrossRef141
Mei-Hong Li, Teresa Sanchez, Harold Yamase, Timothy Hla, Myat Lin Oo, Anna Pappalardo, Kevin R. Lynch, Chen-Yong Lin, Fernando Ferrer. (2009) S1P/S1P1 signaling stimulates cell migration and invasion in Wilms tumor. Cancer Letters 276:2, 171-179
CrossRef142
Masaru Ishii, Jackson G. Egen, Frederick Klauschen, Martin Meier-Schellersheim, Yukihiko Saeki, Jean Vacher, Richard L. Proia, Ronald N. Germain. (2009) Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458:7237, 524-528
CrossRef143
Maria Pia Sormani, Laura Bonzano, Luca Roccatagliata, Gary R. Cutter, Gian Luigi Mancardi, Paolo Bruzzi. (2009) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Annals of Neurology 65:3, 268-275
CrossRef144
Aimee Pasqua Borazanci, Meghan K Harris, Robert N Schwendimann, Eduardo Gonzalez-Toledo, Amir H Maghzi, Masoud Etemadifar, Nadejda Alekseeva, James Pinkston, Roger E Kelley, Alireza Minagar. (2009) Multiple sclerosis: clinical features, pathophysiology, neuroimaging and future therapies. Future Neurology 4:2, 229-246
CrossRef145
Joel S Karliner. (2009) Sphingosine Kinase and Sphingosine 1-Phosphate in Cardioprotection. Journal of Cardiovascular Pharmacology 53:3, 189-197
CrossRef146
Hans-Peter Hartung. (2009) New oral therapies may offer improved treatment options for patients with multiple sclerosis. Current Opinion in Neurology 22:Suppl 1, S10-S14
CrossRef147
Patricia K Coyle. (2009) Existing therapies for multiple sclerosis offer proven efficacy and safety. Current Opinion in Neurology 22:Suppl 1, S4-S9
CrossRef148
A. Quintas-Cardama, J. Cortes. (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:8, 1619-1630
CrossRef149
Jeffrey A. Cohen. (2009) The future of multiple sclerosis treatment. Journal of the Neurological Sciences 277, S55-S61
CrossRef150
Anat Achiron, Sten Fredrikson. (2009) Lessons from randomised direct comparative trials. Journal of the Neurological Sciences 277, S19-S24
CrossRef151
Jean E Merrill. (2009) In Vitro and In Vivo Pharmacological Models to Assess Demyelination and Remyelination. Neuropsychopharmacology 34:1, 55-73
CrossRef152
Lichun Wang, Steven M. Dudek. (2009) Regulation of vascular permeability by sphingosine 1-phosphate. Microvascular Research 77:1, 39-45
CrossRef153
Takanori Kanai, Mamoru Watanabe, Toshifumi Hibi. (2009) Systemically Circulating Colitogenic Memory CD4+T Cells May Be an Ideal Target for the Treatment of Inflammatory Bowel Diseases. The Keio Journal of Medicine 58:4, 203-209
CrossRef154
Toshimitsu FUJII, Mamoru WATANABE. (2009) An additional role of FTY720 in chronic colitis. Japanese Journal of Clinical Immunology 32:1, 7-14
CrossRef155
Kenji CHIBA. (2009) A New Therapeutic Approach for Autoimmune Diseases by the Sphingosine 1-Phosphate Receptor Modulator, Fingolimod (FTY720). YAKUGAKU ZASSHI 129:6, 655-665
CrossRef156
Kenji CHIBA. (2009) A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720). Japanese Journal of Clinical Immunology 32:2, 92-101
CrossRef157
Ghotas Evindar, Sylvie G. Bernier, Malcolm J. Kavarana, Elisabeth Doyle, Jeanine Lorusso, Michael S. Kelley, Keith Halley, Amy Hutchings, Albion D. Wright, Ashis K. Saha, Gerhard Hannig, Barry A. Morgan, William F. Westlin. (2009) Synthesis and evaluation of alkoxy-phenylamides and alkoxy-phenylimidazoles as potent sphingosine-1-phosphate receptor subtype-1 agonists. Bioorganic & Medicinal Chemistry Letters 19:2, 369-372
CrossRef158
Toshimitsu Fujii, Takayuki Tomita, Takanori Kanai, Yasuhiro Nemoto, Teruji Totsuka, Naoya Sakamoto, Tetsuya Nakamura, Kiichiro Tsuchiya, Ryuichi Okamoto, Mamoru Watanabe. (2008) FTY720 suppresses the development of colitis in lymphoid-null mice by modulating the trafficking of colitogenic CD4+ T cells in bone marrow. European Journal of Immunology 38:12, 3290-3303
CrossRef159
Georg Pilz, Peter Wipfler, Gunther Ladurner, Jörg Kraus. (2008) Modern multiple sclerosis treatment – what is approved, what is on the horizon. Drug Discovery Today 13:23-24, 1013-1025
CrossRef160
J. S. Karliner. (2008) Sphingosine kinase regulation and cardioprotection. Cardiovascular Research 82:2, 184-192
CrossRef161
K. Sattler, B. Levkau. (2008) Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovascular Research 82:2, 201-211
CrossRef162
Markus van der Giet, Markus Tölle, Burkhard Kleuser. (2008) Relevance and potential of sphingosine-1-phosphate in vascular inflammatory disease. Biological Chemistry 389:11, 1381-1390
CrossRef163
Rocio S. Lopez-Diego, Howard L. Weiner. (2008) Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary. Nature Reviews Drug Discovery 7:11, 909-925
CrossRef164
Scott E Wenderfer, Stanislaw M Stepkowski, Michael C Braun. (2008) Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney International 74:10, 1319-1326
CrossRef165
Jack P. Antel, Veronique E. Miron. (2008) Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies. Clinical Neurology and Neurosurgery 110:9, 951-957
CrossRef166
Katharine A Whartenby, Donald Small, Peter A Calabresi. (2008) FLT3 inhibitors for the treatment of autoimmune disease. Expert Opinion on Investigational Drugs 17:11, 1685-1692
CrossRef167
Ralf A. Linker, Bernd C. Kieseier, Ralf Gold. (2008) Identification and development of new therapeutics for multiple sclerosis. Trends in Pharmacological Sciences 29:11, 558-565
CrossRef168
Robert A. Bermel, Elizabeth Fisher, Jeffrey A. Cohen. (2008) The Use of MR Imaging as an Outcome Measure in Multiple Sclerosis Clinical Trials. Neuroimaging Clinics of North America 18:4, 687-701
CrossRef169
Veronique E. Miron, Anna Schubart, Jack P. Antel. (2008) Central nervous system-directed effects of FTY720 (fingolimod). Journal of the Neurological Sciences 274:1-2, 13-17
CrossRef170
The CAMMS223 Trial Investigators. (2008) Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis. New England Journal of Medicine 359:17, 1786-1801
Full Text171
Per Soelberg Sorensen, Finn Sellebjerg. (2008) Oral fumarate for relapsing-remitting multiple sclerosis. The Lancet 372:9648, 1447-1448
CrossRef172
Veronique E. Miron, Jeffery A. Hall, Timothy E. Kennedy, Betty Soliven, Jack P. Antel. (2008) Cyclical and Dose-Dependent Responses of Adult Human Mature Oligodendrocytes to Fingolimod. The American Journal of Pathology 173:4, 1143-1152
CrossRef173
Juan Rivera, Richard L. Proia, Ana Olivera. (2008) The alliance of sphingosine-1-phosphate and its receptors in immunity. Nature Reviews Immunology 8:10, 753-763
CrossRef174
, H. Wiendl, K. V. Toyka, P. Rieckmann, R. Gold, H.-P. Hartung, R. Hohlfeld. (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. Journal of Neurology 255:10, 1449-1463
CrossRef175
Alastair Compston, Alasdair Coles. (2008) Multiple sclerosis. The Lancet 372:9648, 1502-1517
CrossRef176
Charles R Mackay. (2008) Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nature Immunology 9:9, 988-998
CrossRef177
Manuel Comabella. (2008) Pharmacogenomics in multiple sclerosis: getting the right medicine to the right patient. Therapy 5:5, 623-629
CrossRef178
C. Infante-Duarte, S. Waiczies, J. Wuerfel, F. Zipp. (2008) New developments in understanding and treating neuroinflammation. Journal of Molecular Medicine 86:9, 975-985
CrossRef179
Emma C. Kerr, David A. Copland, Andrew D. Dick, Lindsay B. Nicholson. (2008) The dynamics of leukocyte infiltration in experimental autoimmune uveoretinitis. Progress in Retinal and Eye Research 27:5, 527-535
CrossRef180
Claudio Gasperini, Luca Ausili Cefaro, Giovanna Borriello, Giuseppe Tosto, Luca Prosperini, Carlo Pozzilli. (2008) Emerging oral drugs for multiple sclerosis. Expert Opinion on Emerging Drugs 13:3, 465-477
CrossRef181
Bianca Weinstock-Guttman, Murali Ramanathan, Robert Zivadinov. (2008) Interferon-β treatment for relapsing multiple sclerosis. Expert Opinion on Biological Therapy 8:9, 1435-1447
CrossRef182
Mary Premenko-Lanier, Nelson B. Moseley, Sarah T. Pruett, Pablo A. Romagnoli, John D. Altman. (2008) Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection. Nature 454:7206, 894-898
CrossRef183
Carolina Ciumas, Alexandra Montavont, Philippe Ryvlin. (2008) Magnetic resonance imaging in clinical trials. Current Opinion in Neurology 24:4, 431-436
CrossRef184
Howard L Weiner. (2008) Oral laquinimod for treatment of relapsing-remitting multiple sclerosis. The Lancet Neurology 7:8, 672-673
CrossRef185
John M. Kovarik, Alan Slade, Gilles-Jacques Riviere, Daniel Neddermann, Steve Maton, Thomas L. Hunt, Robert L. Schmouder. (2008) The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. British Journal of Clinical Pharmacology 66:2, 199-206
CrossRef186
Klemens Högenauer, Andreas Billich, Charles Pally, Markus Streiff, Trixie Wagner, Karl Welzenbach, Peter Nussbaumer. (2008) Phosphorylation by Sphingosine Kinase 2 is Essential for in vivo Potency of FTY720 Analogues. ChemMedChem 3:7, 1027-1029
CrossRef187
Takayuki Kohno, Yasuyuki Igarashi. (2008) Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P. Genes to Cells 13:7, 747-757
CrossRef188
D. Wheeler, V. V. R. Bandaru, P. A. Calabresi, A. Nath, N. J. Haughey. (2008) A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 131:11, 3092-3102
CrossRef189
David B. Sommer, Larry B. Goldstein. 2008. Central Nervous System (CNS). .
CrossRef190
A. Kulakowska, W. Drozdowski, A. Sadzynski, R. Bucki, P. A. Janmey. (2008) Gelsolin concentration in cerebrospinal fluid from patients with multiple sclerosis and other neurological disorders. European Journal of Neurology 15:6, 584-588
CrossRef191
Z. Zhang, U. Fauser, H. J. Schluesener. (2008) Early attenuation of lesional interleukin-16 up-regulation by dexamethasone and FTY720 in experimental traumatic brain injury. Neuropathology and Applied Neurobiology 34:3, 330-339
CrossRef192
Tracy DeAngelis, Fred Lublin. (2008) Multiple sclerosis: new treatment trials and emerging therapeutic targets. Current Opinion in Neurology 21:3, 261-271
CrossRef193
Birgit Sawitzki, Petra Reinke, Hans-Dieter Volk, Kathryn Wood, Laurence A Turka. (2008) Autoimmunity and transplantation: a meeting at the crossroads in Berlin. Nature Immunology 9:5, 447-449
CrossRef194
Alejandro Horga, Xavier Montalban. (2008) FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Review of Neurotherapeutics 8:5, 699-714
CrossRef195
John M. Kovarik, Michael Lu, Gilles-Jacques Riviere, Irene Barbet, Steve Maton, D. Ronald Goldwater, Robert L. Schmouder. (2008) The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. European Journal of Clinical Pharmacology 64:5, 457-463
CrossRef196
A Quintás-Cardama. (2008) Experimental non-ATP-competitive therapies for chronic myelogenous leukemia. Leukemia 22:5, 932-940
CrossRef197
G. Gollmann, H. Neuwirt, C. H. Tripp, H. Mueller, G. Konwalinka, C. Heufler, N. Romani, M. Tiefenthaler. (2008) Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions. International Immunology 20:7, 911-923
CrossRef198
Y.-P. Wu, K. Mizugishi, M. Bektas, R. Sandhoff, R. L. Proia. (2008) Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease. Human Molecular Genetics 17:15, 2257-2264
CrossRef199
Zhiren Zhang, Zhi-Yuan Zhang, Uwe Fauser, Hermann J. Schluesener. (2008) FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Experimental Neurology 210:2, 681-690
CrossRef200
Tracy DeAngelis, Fred Lublin. (2008) Neurotherapeutics in multiple sclerosis: Novel agents and emerging treatment strategies. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 75:2, 157-167
CrossRef201
Susheel Gundewar, David J. Lefer. (2008) Sphingolipid therapy in myocardial ischemia–reperfusion injury. Biochimica et Biophysica Acta (BBA) - General Subjects 1780:3, 571-576
CrossRef202
M.H. Stradner, J. Hermann, H. Angerer, D. Setznagl, I.-G. Sunk, R. Windhager, W.B. Graninger. (2008) Spingosine-1-phosphate stimulates proliferation and counteracts interleukin-1 induced nitric oxide formation in articular chondrocytes. Osteoarthritis and Cartilage 16:3, 305-311
CrossRef203
Matthias P. Wymann, Roger Schneiter. (2008) Lipid signalling in disease. Nature Reviews Molecular Cell Biology 9:2, 162-176
CrossRef204
Q.Y. Li, Y.Y. Chi, S.Q. Liu. (2008) Cell Cycle Arrest Effects of Large-Dose FTY720 on Lymphocytes in Mouse Skin Transplantation Models. Immunopharmacology and Immunotoxicology 30:2, 365-381
CrossRef205
Veronique E. Miron, Cha Gyun Jung, Hye Jung Kim, Timothy E. Kennedy, Betty Soliven, Jack P. Antel. (2008) FTY720 modulates human oligodendrocyte progenitor process extension and survival. Annals of Neurology 63:1, 61-71
CrossRef206
J.A. Stockman. (2008) Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis. Yearbook of Pediatrics 2008, 366-368
CrossRef207
Norimasa Matsumoto, Ryoji Hirose, Shigeo Sasaki, Tetsuro Fujita. (2008) Synthesis of the Key Intermediate, Diethyl 2-Acetylamino-2-(2-(4-octanoylphenyl)ethyl)propane-1,3-dioate, of the Immunomodulatory Agent FTY720 (Fingolimod). CHEMICAL & PHARMACEUTICAL BULLETIN 56:4, 595-597
CrossRef208
Til Menge, Martin S Weber, Bernhard Hemmer, Bernd C Kieseier, Hans-Christian von Büdingen, Clemens Warnke, Scott S Zamvil, Aaron Boster, Omar Khan, Hans-Peter Hartung, Olaf Stüve. (2008) Disease-Modifying Agents for Multiple Sclerosis. Drugs 68:17, 2445-2468
CrossRef209
Kenji CHIBA. (2008) KAGAKU TO SEIBUTSU 46:4, 259-264
CrossRef210
Yasuo Nagaoka, Kota Otsuki, Tetsuro Fujita, Shinichi Uesato. (2008) Effects of Phosphorylation of Immunomodulatory Agent FTY720 (Fingolimod) on Antiproliferative Activity against Breast and Colon Cancer Cells. Biological & Pharmaceutical Bulletin 31:6, 1177-1181
CrossRef211
Kumlesh K. Dev, Florian Mullershausen, Henri Mattes, Rainer R. Kuhn, Graeme Bilbe, Daniel Hoyer, Anis Mir. (2008) Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis. Pharmacology & Therapeutics 117:1, 77-93
CrossRef212
Susan R Schwab, Jason G Cyster. (2007) Finding a way out: lymphocyte egress from lymphoid organs. Nature Immunology 8:12, 1295-1301
CrossRef213
C. G. Jung, H. J. Kim, V. E. Miron, S. Cook, T. E. Kennedy, C. A. Foster, J. P. Antel, B. Soliven. (2007) Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 55:16, 1656-1667
CrossRef214
R. Gold, P. Rieckmann. (2007) Fortschritte im Verständnis von Pathogenese und Immuntherapie der Multiplen Sklerose. Der Nervenarzt 78:S1, 15-26
CrossRef215
B. A. Cohen, P. Rieckmann. (2007) Emerging oral therapies for multiple sclerosis. International Journal of Clinical Practice 61:11, 1922-1930
CrossRef216
X.-Z. Yu, C. Anasetti. (2007) FTY720 prevents GVHD: the host perspective. Blood 110:9, 3094-3094
CrossRef217
Paolo A. Muraro, Bibiana Bielekova. (2007) Emerging therapies for multiple sclerosis. Neurotherapeutics 4:4, 676-692
CrossRef218
T. Holmøy, F. Vartdal. (2007) The Immunological Basis for Treatment of Multiple Sclerosis. Scandinavian Journal of Immunology 66:4, 374-382
CrossRef219
J. Klatt, H.-P. Hartung, R. Hohlfeld. (2007) FTY720 (Fingolimod) als neue Therapiemöglichkeit der Multiplen Sklerose. Der Nervenarzt 78:10, 1200-1208
CrossRef220
Balázs Balatoni, Maria K. Storch, Eva-M. Swoboda, Vinzenz Schönborn, Agnieszka Koziel, George N. Lambrou, Peter C. Hiestand, Robert Weissert, Carolyn A. Foster. (2007) FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Research Bulletin 74:5, 307-316
CrossRef221
María L. del Rio, Oliver Pabst, Pablo Ramirez, Giovanna Penuelas-Rivas, Reinhold Förster, Jose-Ignacio Rodriguez-Barbosa. (2007) The thymus is required for the ability of FTY720 to prolong skin allograft survival across different histocompatibility MHC barriers. Transplant International 20:10, 895-903
CrossRef222
Richard Rivera, Jerold Chun. (2007) Potential therapeutic roles of lysophospholipid signaling in autoimmune-related disease. Future Lipidology 2:5, 535-545
CrossRef223
Bernhard Hemmer, Hans-Peter Hartung. (2007) Toward the development of rational therapies in multiple sclerosis: what is on the horizon?. Annals of Neurology 62:4, 314-326
CrossRef224
Henry F McFarland, Roland Martin. (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nature Immunology 8:9, 913-919
CrossRef225
Youssef H. Zeidan, Yusuf A. Hannun. (2007) Translational aspects of sphingolipid metabolism. Trends in Molecular Medicine 13:8, 327-336
CrossRef226
C. Kleinschnitz, S.G. Meuth, B.C. Kieseier, H. Wiendl. (2007) Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen. Der Nervenarzt 78:8, 883-911
CrossRef227
Jeffrey I. Greenstein. (2007) Current concepts of the cellular and molecular pathophysiology of multiple sclerosis. Developmental Neurobiology 67:9, 1248-1265
CrossRef228
Florian Mullershausen, Luis M. Craveiro, Youngah Shin, Marta Cortes-Cros, Frederic Bassilana, Maribel Osinde, William L. Wishart, Danilo Guerini, Michaela Thallmair, Martin E. Schwab, Rajeev Sivasankaran, Klaus Seuwen, Kumlesh K. Dev. (2007) Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. Journal of Neurochemistry 102:4, 1151-1161
CrossRef229
Volker Brinkmann. (2007) Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacology & Therapeutics 115:1, 84-105
CrossRef230
Julie M. Yabu, Flavio Vincenti. (2007) Novel Immunosuppression: Small Molecules and Biologics. Seminars in Nephrology 27:4, 479-486
CrossRef231
Norra MacReady. (2007) Aaron Miller, MD. Neurology Today 7:14, 9-11
CrossRef232
Klaus G. Petry, Claudine Boiziau, Vincent Dousset, Bruno Brochet. (2007) Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics 4:3, 434-442
CrossRef233
Kyeok Kim, Yu-Lee Kim, Santosh J. Sacket, Hyo-Lim Kim, Mijin Han, Deok Seong Park, Baeck Kyoung Lee, Won Koo Lee, Hyun-Joon Ha, Dong-Soon Im. (2007) Sphingosine 1-phosphate (S1P) induces shape change in rat C6 glioma cells through the S1P 2 receptor: development of an agonist for S1P receptors. Journal of Pharmacy and Pharmacology 59:7, 1035-1041
CrossRef234
Maikel Jongsma, Urszula M. Florczyk, Mariëlle C. Hendriks-Balk, Martin C. Michel, Stephan L. M. Peters, Astrid E. Alewijnse. (2007) Validation of a rapid, non-radioactive method to quantify internalisation of G-protein coupled receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 375:5, 329-336
CrossRef235
William H. Stuart. (2007) Combination therapy for the treatment of multiple sclerosis: challenges and opportunities. Current Medical Research and Opinion 23:6, 1199-1208
CrossRef236
Bernd C Kieseier, Heinz Wiendl, Bernhard Hemmer, Hans-Peter Hartung. (2007) Treatment and treatment trials in multiple sclerosis. Current Opinion in Neurology 20:3, 286-293
CrossRef237
W.A. Lagrèze. (2007) Steroide bei Sehnerverkrankungen?. Der Ophthalmologe 104:6, 517-520
CrossRef238
Florian Mullershausen, Luis M. Craveiro, Youngah Shin, Marta Cortes-Cros, Frederic Bassilana, Maribel Osinde, William L. Wishart, Danilo Guerini, Michaela Thallmair, Martin E. Schwab, Rajeev Sivasankaran, Klaus Seuwen, Kumlesh K. Dev. (2007) Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. Journal of Neurochemistry 0:0, 070508225918002-???
CrossRef239
Adrienne Boissy, Robert J. Fox. (2007) Current treatment options in multiple sclerosis. Current Treatment Options in Neurology 9:3, 176-186
CrossRef240
Jodie M. Burton, Paul O’Connor. (2007) Novel oral agents for multiple sclerosis. Current Neurology and Neuroscience Reports 7:3, 223-230
CrossRef241
Maribel Osinde, Florian Mullershausen, Kumlesh K. Dev. (2007) Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 52:5, 1210-1218
CrossRef242
Sebastian Martini, Harm Peters, Torsten Böhler, Klemens Budde. (2007) Current perspectives on FTY720. Expert Opinion on Investigational Drugs 16:4, 505-518
CrossRef243
Shumei Man, Eroboghene E. Ubogu, Richard M. Ransohoff. (2007) Inflammatory Cell Migration into the Central Nervous System: A Few New Twists on an Old Tale. Brain Pathology 17:2, 243-250
CrossRef244
Erik Schadde, Stuart J. Knechtle. (2007) Review: chemokines in transplantation. Transplantation Reviews 21:2, 107-118
CrossRef245
Jeffrey L. Cummings. (2007) Progress in Neurotherapeutics and Neuropsychopharmacology 2007. Progress in Neurotherapeutics and Neuropsychopharmacology 2, 1
CrossRef246
Thomas Baumruker, Andreas Billich, Volker Brinkmann. (2007) FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opinion on Investigational Drugs 16:3, 283-289
CrossRef247
Dr Nicola Gullick, Dr David D’Cruz. (2007) New therapies for the treatment of systemic lupus erythematosus. Expert Opinion on Therapeutic Patents 17:3, 299-313
CrossRef248
Akio Kihara, Susumu Mitsutake, Yukiko Mizutani, Yasuyuki Igarashi. (2007) Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate. Progress in Lipid Research 46:2, 126-144
CrossRef249
Zhiyuan Zhang, Zhiren Zhang, Uwe Fauser, Matthias Artelt, Michael Burnet, Hermann J. Schluesener. (2007) FTY720 attenuates accumulation of EMAP-II + and MHC-II + monocytes in early lesions of rat traumatic brain injury. Journal of Cellular and Molecular Medicine 11:2, 307-314
CrossRef250
Sheila A Doggrell. (2007) Is fingolimod an advancement in the treatment of multiple sclerosis?. Expert Opinion on Pharmacotherapy 8:3, 383-386
CrossRef251
Bernd C Kieseier, Heinz Wiendl. (2007) Oral Disease-Modifying Treatments for Multiple Sclerosis. CNS Drugs 21:6, 483-502
CrossRef252
David Miller. (2007) Multiple sclerosis: new insights and therapeutic progress. The Lancet Neurology 6:1, 5-6
CrossRef253
Eric H Liu, Richard M Siegel, David M Harlan, John J O'Shea. (2007) T cell–directed therapies: lessons learned and future prospects. Nature Immunology 8:1, 25-30
CrossRef254
(2007) Fingolimod shows therapeutic potential for relapsing multiple sclerosis. Nature Clinical Practice Neurology 3:1, 8-8
CrossRef255
Hartmut Wekerle, Florian C. Kurschus. (2006) Animal models of multiple sclerosis. Drug Discovery Today: Disease Models 3:4, 359-367
CrossRef256
, Peter Rieckmann. (2006) Immunmodulatorische Stufentherapie der Multiplen Sklerose. Der Nervenarzt 77:12, 1506-1518
CrossRef257
Robert Weissert. (2006) The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived. Expert Review of Neurotherapeutics 6:11, 1587-1590
CrossRef258
Massberg, Steffen, von Andrian, Ulrich H., . (2006) Fingolimod and Sphingosine-1-Phosphate — Modifiers of Lymphocyte Migration. New England Journal of Medicine 355:11, 1088-1091
Full Text
